EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cost-Effectiveness of One-Time Universal Childhood Hepatitis C Screening in the United States

Jessica Frankeberger iD, Melissa Choz, Tatyana Kushner, Nancy Reau, Lily Ostrer, Adriane Wynn, Natasha K Martin

Journal of the Pediatric Infectious Diseases Society · 2026

DOI: 10.1093/jpids/piag005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, 2026. Verfasst von Jessica Frankeberger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of California, San Diego, CA, United States. Hauptthemen laut MEDLINE: Mass Screening, Hepatitis C. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH National Heart, Lung, and Blood Institute, NIH National Institute of Allergy and Infectious Disease, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatitis C Virus (HCV) in pregnancy has increased, leading to increased perinatally exposed infants. Although universal HCV screening in pregnancy is recommended, pediatric cases remain undiagnosed. We examine the cost-effectiveness of universal HCV screening among children at age 2 and 10, when other routine blood testing is recommended.

Methods

An HCV natural history Markov model evaluated the cost-effectiveness of universal HCV screening independently at ages 2 and 10 compared to the currently recommended risk-based screening of children born to those with HCV. Based on previous literature, we assumed a 0.05% pediatric HCV chronic prevalence (0.73% chronic prevalence among pregnant persons and 7.2% vertical transmission). In the status-quo scenario, we assumed 23% of children with prenatal HCV exposure were screened. We assessed costs (United States Dollar), quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER, $ per QALY gained) compared to a willingness-to-pay threshold (WTP) of $50 000/QALY. We explored parameter uncertainty, including pediatric HCV chronic prevalence and screening rates, in multiple sensitivity analyses.

Results

Universal HCV screening at age 2 was cost-effective (ICER = $8774/QALY gained) compared to the status-quo risk-based screening. The lowest pediatric HCV chronic prevalence in which universal screening remained cost-effective under a WTP of $50 000/QALY was 0.007%. At age 10, universal screening was cost-effective compared to risk-based screening (ICER = $4404/gained) and was cost-effective at the lowest HCV prevalence in children of 0.006%. Models at both age 2 and 10 were robust to sensitivity analyses.

Conclusions

Universal HCV screening in childhood is cost-effective. Guidelines should consider recommending universal screening nationally, particularly if it can be conducted along with other routine pediatric blood draws.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mass ScreeningHepatitis CHumansCost-Benefit AnalysisCost-Effectiveness AnalysisUnited StatesFemaleChild, PreschoolChildQuality-Adjusted Life YearsPregnancyMarkov ChainsInfectious Disease Transmission, VerticalPrevalence

Stichwörter der Autor:innen

HCVcost-effectivenesshealth economicspediatric HCVperinatal transmissionscreening

Autor:innen und Institutionen

  • Department of Pediatrics, University of California, San Diego, CA, United States.
  • Division of Infectious Diseases and Global Public Health, University of California, San Diego, CA, United States.
  • Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY, United States.
  • Division of Obstetrics & Gynecology, Weill Cornell Medicine, New York, NY, United States.
  • Section of Hepatology, Rush University Medical Center, Chicago, IL, United States.

ORCID-Profile: Jessica Frankeberger

Förderung

  • NIH National Heart, Lung, and Blood Institute
  • NIH National Institute of Allergy and Infectious Disease
  • NIAID NIH HHS
  • NIH HHS
  • NIDA NIH HHS
  • NHLBI NIH HHS
  • National Institutes of Health
  • National Institute on Drug Abuse

Zitieren

APA

Frankeberger, J., Choz, M., Kushner, T., Reau, N., Ostrer, L., Wynn, A., & Martin, N. K. (2026). Cost-Effectiveness of One-Time Universal Childhood Hepatitis C Screening in the United States. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piag005

Vancouver

Frankeberger J, Choz M, Kushner T, Reau N, Ostrer L, Wynn A, et al. Cost-Effectiveness of One-Time Universal Childhood Hepatitis C Screening in the United States. Journal of the Pediatric Infectious Diseases Society. 2026. doi:10.1093/jpids/piag005

BibTeX
@article{Frankeberger2026,
  author = {Frankeberger, Jessica and Choz, Melissa and Kushner, Tatyana and Reau, Nancy and Ostrer, Lily and Wynn, Adriane and Martin, Natasha K},
  title = {Cost-Effectiveness of One-Time Universal Childhood Hepatitis C Screening in the United States},
  journal = {Journal of the Pediatric Infectious Diseases Society},
  year = {2026},
  doi = {10.1093/jpids/piag005}
}
Kostenlos starten →